Pharmaceutical supply chains are among the most heavily regulated and most closely tracked in any sector. They are also, in practice, among the least joined up.

Serialisation requirements have produced enormous quantities of data, but the systems holding it were often built to satisfy a regulation rather than to support operations.

The result is a supply chain that can prove where a pack has been while struggling to say where it is now.

Serialisation solved authentication, not visibility

Regulations across major markets require unique identifiers at the saleable unit level, verification at defined points, and the ability to trace a product’s history. In the United States this sits under the Drug Supply Chain Security Act; comparable regimes operate in the European Union and elsewhere.

These frameworks were designed to keep falsified medicines out of the legitimate supply chain, and by that measure they work. What they do not deliver is operational visibility. Verification happens at discrete handover points. Between those points, the identifier exists in a database but the pack itself is not tracked continuously.

For a supply chain team trying to answer where a specific batch currently sits, or when it will arrive, serialisation data is a record of the past rather than a live picture. Many organisations discovered this during periods of disruption, when the systems that could reconstruct a full pedigree could not forecast a shortage two weeks out.

Cold chain data is collected but often not connected

Temperature-controlled distribution has its own instrumentation. Data loggers travel with shipments, refrigerated units report their own status, and warehouse systems monitor storage conditions continuously.

The common weakness is that these datasets sit apart from each other and apart from the transport management system. A logger is read on arrival. If an excursion occurred, it is discovered after the shipment has already reached its destination — at which point the options are limited to accepting or rejecting the consignment.

Connected monitoring changes the decision point. A shipment reporting a rising trend while still in transit can be rerouted to a nearer facility, prioritised for unloading, or flagged for inspection before it joins general stock. The difference in value is substantial for high-cost biologics, where a single rejected consignment can exceed the annual cost of the monitoring system.

The obstacle is rarely the sensors. It is that logger data, vehicle telematics, warehouse management and the ERP are four separate systems, frequently from four vendors, with no shared identifier for the shipment.

Forecasting is limited by what the upstream partner will share

Demand forecasting in pharmaceutical distribution is constrained less by modelling technique than by data access. A manufacturer forecasting demand often has good visibility of its own shipments to wholesalers and poor visibility of what wholesalers hold and what moves onward to pharmacies and hospitals.

This produces the familiar amplification effect, where modest variation in end demand becomes large swings in upstream orders. Long lead times and batch release testing make the consequences slower to correct than in most sectors.

Improving this is a commercial negotiation as much as a technical project. Where partners agree to share inventory positions and sell-through data, forecast accuracy improves substantially. Where they do not, the most sophisticated model available is still working from a partial view.

Organisations that have made progress here usually started narrow — a single product family with a single major distribution partner — and expanded once the arrangement demonstrated value to both parties rather than only to the manufacturer.

Integration is the recurring bottleneck

A pattern runs through all three of these areas. The instrumentation exists. The data is being generated. What is missing is the connective layer that lets one system’s output become another system’s input.

This is unglamorous work. It involves reconciling identifiers across systems that name the same shipment differently, handling the reality that partners exchange data in formats ranging from modern APIs to flat files sent on a schedule, and building tolerance for feeds that arrive late or incomplete without corrupting downstream calculations.

It is also where most of the effort in these projects actually goes. Teams scoping IT solutions for the pharmaceutical industry typically find the integration and data reconciliation work considerably larger than the analytical or interface components, and schedules built on the opposite assumption tend to slip.

Validation adds a further constraint. Systems that influence decisions about product quality or distribution fall within regulated computer system validation requirements. Changes cannot be deployed continuously in the way they might be in an unregulated environment, and this needs to be reflected in how releases are planned.

A reasonable starting point

For organisations deciding where to begin, the most productive first step is usually an honest inventory: which systems hold supply chain data, what identifier each uses for the same physical object, and where those identifiers can be reconciled.

That exercise is unexciting and frequently reveals that the same shipment carries four different reference numbers with no authoritative mapping between them. It is also the foundation for everything else. Without it, each analytical project rebuilds the same reconciliation logic separately, and the organisation accumulates parallel versions of the truth rather than a single one.